Jain Global LLC Boosts Stake in Pfizer Inc. $PFE

Key Points

• Jain Global LLC increased its stake in Pfizer by 32.3% in the third quarter, adding 98,303 shares to hold 402,600 shares worth about $10.26 million.
• Pfizer beat Q4 expectations with earnings of $0.66 per share (vs. $0.57 expected) and revenue of $17.56 billion (vs. $16.93 billion expected), though revenue was down 1.2% year-over-year.
• Analysts' consensus is a Hold with an average price target of $28.05 amid mixed ratings (1 Strong Buy, 5 Buy, 14 Hold, 3 Sell); the stock trades near $26.61 with a market cap of about $151.3 billion and a P/E of 19.56.

Jain Global LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 32.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 402,600 shares of the biopharmaceutical company's stock after acquiring an additional 98,303 shares during the quarter. Jain Global LLC's holdings in Pfizer were worth $10,258,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. KKM Financial LLC lifted its stake in Pfizer by 28.9% in the 3rd quarter. KKM Financial LLC now owns 149,996 shares of the biopharmaceutical company's stock worth $3,822,000 after purchasing an additional 33,601 shares in the last quarter. Hilltop Holdings Inc. grew its position in shares of Pfizer by 31.8% in the third quarter. Hilltop Holdings Inc. now owns 160,627 shares of the biopharmaceutical company's stock valued at $4,093,000 after purchasing an additional 38,758 shares in the last quarter. Hollow Brook Wealth Management LLC grew its position in shares of Pfizer by 5.9% in the third quarter. Hollow Brook Wealth Management LLC now owns 140,151 shares of the biopharmaceutical company's stock valued at $3,571,000 after purchasing an additional 7,797 shares in the last quarter. Gotham Asset Management LLC increased its holdings in shares of Pfizer by 62.8% in the third quarter. Gotham Asset Management LLC now owns 1,472,086 shares of the biopharmaceutical company's stock valued at $37,509,000 after purchasing an additional 568,016 shares during the last quarter. Finally, Fred Alger Management LLC lifted its position in Pfizer by 1.1% during the third quarter. Fred Alger Management LLC now owns 132,850 shares of the biopharmaceutical company's stock worth $3,385,000 after buying an additional 1,461 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on PFE. UBS Group assumed coverage on Pfizer in a research note on Tuesday, January 6th. They set a "neutral" rating and a $25.00 price objective on the stock. BMO Capital Markets reiterated an "outperform" rating and set a $30.00 price target on shares of Pfizer in a report on Monday, March 9th. Citigroup initiated coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They set a "neutral" rating and a $26.00 price target on the stock. Barclays assumed coverage on shares of Pfizer in a report on Thursday, February 19th. They issued an "underweight" rating and a $25.00 price objective for the company. Finally, Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $28.05.

Pfizer Price Performance

NYSE:PFE opened at $26.61 on Tuesday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94. The stock's fifty day moving average is $26.53 and its two-hundred day moving average is $25.54. The company has a market capitalization of $151.28 billion, a P/E ratio of 19.56 and a beta of 0.47. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts' consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analysts' expectations of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company's revenue was down 1.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.63 EPS. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.